Open Access

Cancer drug delivery in the nano era: An overview and perspectives (Review)

  • Authors:
    • Zhen Li
    • Shirui Tan
    • Shuan Li
    • Qiang Shen
    • Kunhua Wang
  • View Affiliations

  • Published online on: June 14, 2017     https://doi.org/10.3892/or.2017.5718
  • Pages: 611-624
  • Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Nanomaterials are increasingly used as drug carriers for cancer therapy. Nanomaterials also appeal to researchers in the areas of cancer diagnosis and biomarker discovery. Several antitumor nanodrugs are currently being tested in preclinical and clinical trials and show promise in therapeutic and other settings. We review the development of nanomaterial drug carriers, including liposomes, polymer nanoparticles, dendritic polymers, and nanomicelles, for the diagnosis and treatment of various cancers. The prospects of nanomaterials as drug carriers for future clinical applications are also discussed.
View Figures
View References

Related Articles

Journal Cover

August-2017
Volume 38 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Li Z, Tan S, Li S, Shen Q and Wang K: Cancer drug delivery in the nano era: An overview and perspectives (Review). Oncol Rep 38: 611-624, 2017
APA
Li, Z., Tan, S., Li, S., Shen, Q., & Wang, K. (2017). Cancer drug delivery in the nano era: An overview and perspectives (Review). Oncology Reports, 38, 611-624. https://doi.org/10.3892/or.2017.5718
MLA
Li, Z., Tan, S., Li, S., Shen, Q., Wang, K."Cancer drug delivery in the nano era: An overview and perspectives (Review)". Oncology Reports 38.2 (2017): 611-624.
Chicago
Li, Z., Tan, S., Li, S., Shen, Q., Wang, K."Cancer drug delivery in the nano era: An overview and perspectives (Review)". Oncology Reports 38, no. 2 (2017): 611-624. https://doi.org/10.3892/or.2017.5718